First New Asthma and COPD Treatment in 50 Years Shows Promise

Benralizumab, an injectable monoclonal antibody, outperforms steroids in clinical trials, potentially revolutionizing care for respiratory flare-ups.

Benralizumab targets eosinophils, a type of white blood cell, to reduce lung inflammation during asthma and COPD attacks.
A clinical trial involving 158 patients found benralizumab reduced treatment failures by 30% compared to steroids, with fewer hospitalizations and improved symptoms.
Patients reported better quality of life and fewer side effects compared to traditional steroid treatments, which carry risks like diabetes and osteoporosis.
The drug is currently used for severe asthma in low doses, but a higher dose during flare-ups shows significant potential for broader application.
Further large-scale trials are planned to confirm its effectiveness and assess cost feasibility before widespread availability.